by treadwell | Aug 12, 2020 | Uncategorized
Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC):...
by treadwell | Jun 2, 2020 | Uncategorized
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor,...
Recent Comments